RxDoctor Payments Data

Jason McClune, MD

Pulmonary Disease · Jacksonville, FLNPI 1467677914

Payments from drug & device makers

$75,338in general payments, 2019–2025

Across 298 payments — averaging $252.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$65K
  • Intuitive Surgical$4K
  • GSK$849
  • AstraZeneca$693
  • Johnson & Johnson$503
  • Regeneron Healthcare Solutions, Inc.$503
  • plus $4K from 42 others

What the payments were for

  • Travel & lodging$1,16211%
  • Food & beverage$6,47663%
  • Education$2,69826%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,338 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$106,694
Medicare patients
405
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter307$358,389
Tyvaso DpiTreprostinil13$305,043
Dupixent PenDupilumab48$232,535
ArikayceAmikacin Liposomal/Neb.Accessr11$167,742
OfevNintedanib Esylate11$145,817
Fasenra PenBenralizumab18$100,689
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr85$60,497
Breo ElliptaFluticasone/Vilanterol96$59,954
Breztri AerosphereBudesonide/Glycopyr/Formoterol71$59,369
NucalaMepolizumab13$47,964
XolairOmalizumab12$38,568
SymbicortBudesonide/Formoterol Fumarate75$35,770
Spiriva RespimatTiotropium Bromide27$28,265
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$26,274
EliquisApixaban27$22,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta$849$532,132513 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$239$200,35670 claims
Insmed, Inc.Arikayce$147$167,74211 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$693$102,217159 claims
PfizerEliquis$18$22,64227 claims
MerckDulera$131$3,79611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →